{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:46Z","timestamp":1791489646370,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":231,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101400","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:35:23Z","timestamp":1789724123000},"page":"101400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tissue factor-targeted antibody-drug conjugates in cervical cancer: Focus on tisotumab vedotin"],"prefix":"10.1016","volume":"49","author":[{"given":"Mengyuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10167","key":"10.1016\/j.ctarc.2026.101400_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101400_bib0002","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin. Med. J. (Engl)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101400_bib0003","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101400_bib0004","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"issue":"10103","key":"10.1016\/j.ctarc.2026.101400_bib0005","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101400_bib0006","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/cancers16142541","article-title":"Management for cervical cancer patients: a comparison of the guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)","volume":"16","author":"Restaino","year":"2024","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101400_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000642","article-title":"Novel antibody\u2013drug conjugates: current and future roles in gynecologic oncology","volume":"33","author":"Tymon-Rosario","year":"2021","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101400_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-drug conjugates in gynecologic cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.ctarc.2026.101400_bib0009","unstructured":"\u201cA smarter health through the internet of surgical things - PubMed.\u201d 2022 Accessed: Jul. 19, 2026. [Online]. Available: https:\/\/webvpn.ahmu.edu.cn\/https:\/\/77726476706e69737468656265737421e0e243912234265e7d0a80e296592e7bb7d62ae2c192eb\/35746359\/."},{"key":"10.1016\/j.ctarc.2026.101400_bib0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5114\/amsad\/209721","article-title":"3D printing in medicine: bridging imaging, education, and practice","volume":"10","author":"S","year":"2025","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"10.1016\/j.ctarc.2026.101400_bib0011","article-title":"Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101400_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299345","article-title":"Glyoxalase 1: emerging biomarker and therapeutic target in cervical cancer progression","volume":"19","author":"Kim","year":"2024","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101400_bib0013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis, and vascular development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101400_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.28959","article-title":"The role of tissue factor isoforms in cancer biology","volume":"137","author":"Leppert","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2026.101400_bib0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/jth.12222","article-title":"Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill","volume":"11","author":"Kocat\u00fcrk","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ctarc.2026.101400_bib0016","unstructured":"\u201cTissue factor\/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells - PubMed.\u201d 2008 Accessed: Dec. 01, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/18325115\/."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101400_bib0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"Ahmadi","year":"2023","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101400_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","article-title":"The extracellular matrix in tumor progression and metastasis","volume":"36","author":"Eble","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101400_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue factor and cancer: regulation, tumor growth, and metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101400_bib0020","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","article-title":"Role of tissue factor in cancer","volume":"27","author":"Kasthuri","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101400_bib0021","first-page":"4075","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101400_bib0022","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101400_bib0023","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab Vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101400_bib0024","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101400_bib0025","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101400_bib0026","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101400_bib0027","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/10600280221118370","article-title":"A review of Tisotumab Vedotin-tftv in recurrent or metastatic cervical cancer","volume":"57","author":"Heitz","year":"2023","journal-title":"Ann. Pharmacother"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101400_bib0028","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.ctarc.2026.101400_bib0029","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab Vedotin in combination with carboplatin, Pembrolizumab, or Bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101400_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241277647","article-title":"Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art","volume":"16","author":"Camarda","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101400_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1538980","article-title":"The efficacy and safety of Tisotumab vedotin in the treatment of recurrent\/metastatic cervical cancer: a systematic review and meta-analysis of single-arm studies","volume":"16","author":"Zeng","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101400_bib0032","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN Guidelines\u00ae insights: cervical Cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101400_bib0033","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101400_bib0034","unstructured":"\u201cAntibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen - PubMed.\u201d 2006 Accessed: Dec. 06, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/16540673\/."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101400_bib0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to Trastuzumab Emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101400_bib0036","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"issue":"Suppl","key":"10.1016\/j.ctarc.2026.101400_bib0037","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101400_bib0038","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101400_bib0039","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101400_bib0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101400_bib0041","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1535-7163.MCT-18-0471","article-title":"Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting","volume":"17","author":"Theunissen","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101400_bib0042","first-page":"538","article-title":"Three dimensional conformal versus volumetric arc therapy in gynecological cancer: a retrospective study evaluating therapeutic effect and toxicity","volume":"120","author":"I","year":"2025","journal-title":"Chirurgia (Bucharest, Romania : 1990)"},{"key":"10.1016\/j.ctarc.2026.101400_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1395784","article-title":"Progress in the study of antibody-drug conjugates for the treatment of cervical cancer","volume":"14","author":"Zhai","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101400_bib0044","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ctarc.2026.101400_bib0045","unstructured":"B. Wilkin, \u201cThe future of antibody-drug conjugates: advances in bioconjugation, linkers, and payload optimization.\u201d 2025 Accessed: Dec. 06, 2025. [Online]. Available: https:\/\/blog.crownbio.com\/cancer-research\/adc-development-advances-bioconjugation-linkers-payload-optimization."},{"key":"10.1016\/j.ctarc.2026.101400_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102453","article-title":"Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions","volume":"59","author":"Ulvang","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101400_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2025.09.001","article-title":"Sacituzumab govitecan in Chinese patients with recurrent\/metastatic cervical cancer: results from the phase 2 EVER-132-003 basket study (NCT05119907)","volume":"202","author":"An","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101400_bib0048","article-title":"Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101400_bib0049","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5455\/msm.2024.36.268-279","article-title":"Exploring Bevacizumab\u2019s role in gynecological cancers: an up-to-date narrative review focusing on ovarian cancer","volume":"36","author":"E","year":"2024","journal-title":"Mater. Sociomed."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:45:09Z","timestamp":1791488709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"alternative-id":["S2468294226003114"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101400","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue factor-targeted antibody-drug conjugates in cervical cancer: Focus on tisotumab vedotin","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101400"}}